Pancreatic cancer, treatment options, and GI-4000

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 11, 2014, Pages 3347-3353

  Hartley, Marion L ^a   Bade, Najeebah A ^a   Prins, Petra A ^a   Ampie, Leonel ^a   Marshall, John L ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; ERLOTINIB; FLUOROURACIL; GAMMA INTERFERON; GEMCITABINE; GI 4000; INTERLEUKIN 2; IRINOTECAN; MUCIN 1; OXALIPLATIN; PACLITAXEL; PLACEBO; PROTEIN P16; PROTEIN P53; PROTEOME; RAS PROTEIN; SMAD4 PROTEIN; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANTIGEN PRESENTING CELL; BONE MARROW SUPPRESSION; CANCER EPIDEMIOLOGY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG FATALITY; DRUG TARGETING; FATIGUE; GENETIC CODE; HUMAN; MONOTHERAPY; MUTATIONAL ANALYSIS; NEUROPATHY; NEUTROPENIA; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS SURGERY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; REVIEW; SURVIVAL RATE; TUMOR IMMUNITY; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT; CARCINOMA, PANCREATIC DUCTAL; CYTOTOXIC T LYMPHOCYTE; GENETICS; HELPER CELL; IMMUNOLOGY; IMMUNOTHERAPY; PANCREATIC NEOPLASMS; PROCEDURES; VACCINATION;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA, PANCREATIC DUCTAL; HUMANS; IMMUNOTHERAPY; PANCREATIC NEOPLASMS; RAS PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; VACCINATION;

EID: 84921815396     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2014.1004017     Document Type: Review

References (63)

1. American Cancer Society. American cancer society. Cancer FactsFigures 2014; Atlanta; 2014.
2. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006; 244(1):10-5; PMID:16794383.
3. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993; 165:68-72; discussion 72-73; PMID:8380315.
4. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 2003; 237(1):74-85; PMID:12496533.
5. Liao WC, Chien KL, Lin YL, Wu MS, Lin JT, Wang HP, Tu YK. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol 2013; 14:1095-103; PMID:24035532.
6. Yu Z, Zhong W, Tan Z-M, Wang L-Y, Yuan Y-H. Gemcitabine adjuvant therapy for resected pancreatic cancer: a meta-analysis. Am J Clin Oncol 2013; Aug 7 (Epub ahead of print); PMID:23934134.
7. Krzyzanowska MK, Weeks JC, Earle CC. Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness. J Clin Oncol 2003; 21(18):3409-14; PMID:12972517.
8. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of canada clinical trials group. J Clin Oncol 2007; 25:1960-6; PMID:17452677
9. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer; N Engl J Med. 2011; 364(19):1817-25; PMID:21561347.
10. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369(18):1691-703; PMID:24131140.
11. Goldstein D, Hassan R, Maraghi E, et al. Updated survival from a randomized phase III trial (MPACT) of nab -paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas. J Clin Oncol 32, 2014 (suppl 3; abstr 178).
12. Von Hoff DD, Goldstein D, Renschler MF. Albuminbound paclitaxel plus gemcitabine in pancreatic cancer. N Engl J Med 2014; 370(5):479-80; PMID:24476438.
13. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm367613.htm.
14. Hauschild A, Volkenandt M. [Adjuvant therapy of malignant melanoma]. Ther. Umsch. 1999; 56(6):324-9. Available at: http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/636/CN-00165636/frame.html;PMID:10420815.
15. Hauschild A. Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations? Curr Oncol 2009; 16(3):3-6. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2695706&tool=pmcentrez&rendertype=abstract; PMID:19526078; http://dx.doi.org/10.3747/co.v16i3.447
16. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer; J Clin Oncol. 2003; 21(16):3127-32; PMID:12915604
17. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995; 87:982-90; PMID:7629885.
18. Marshall JL, Hawkins MJ, Tsang KY, Richmond E, Pedicano JE, Zhu MZ, Schlom J. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol. 1999; 17(1):332-7; PMID:10458251
19. Bilusic M1, Heery CR, Arlen PM, Rauckhorst M, Apelian D, Tsang KY, Tucker JA, Jochems C, Schlom J, Gulley JLMR. Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunol Immunother 2014; 63(3):225-34; PMID:24327292.
20. Nordqvist C. Therion Reports Results of Phase 3 PANVAC-VF Trial and Announces Plans for Company Sale [Press Release]. PR Newswire. http://www.lifesciencesworld.com/news/view/7586. Published 2006.
21. Rahma OE, Khleif SN. Therapeutic vaccines for gastrointestinal cancers. Gastroenterol Hepatol 2011; 7(8): 517-527 (then 563-564); PMID:22298988
22. Azijli K, Stelloo E, Peters GJ, VAN DEN Eertwegh AJM. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies. Anticancer Res 2014; 34(4):1493-505. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24692676; PMID:24692676
23. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, et al. Nivolumab for metastatic renal cell carcinoma (mRCC): results of a randomized, dose-ranging phase II trial. J Clin Oncol 32:5s, 2014 (suppl; abstr 5009). Available at: http://meeting.ascopubs.org/cgi/content/abstract/32/15-suppl/5009; PMID:25452452.
24. Amin A, Plimack ER, Infante JR, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 32:5s, 2014 (suppl; abstr 5010);. Available at: http://meeting.ascopubs.org/cgi/content/abstract/32/15-suppl/5010
25. Hammers HJ, Plimack ER, Infante JR, et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J Clin Oncol 32:5s, 2014 (suppl; abstr 4504); Available at: http://meeting.ascopubs.org/cgi/content/abstract/32/15-suppl/4504
26. Bryant KL, Mancias JD, Kimmelman AC, Der CJ. KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci 2014; 39(2):91-100; PMID:24388967.
27. Zorde Khvalevsky E, Gabai R, Rachmut IH, Horwitz E, Brunschwig Z, Orbach A, Shemi A, Golan T, Domb AJ, Yavin E, et al. Mutant KRAS is a druggable target for pancreatic cancer. Proc Natl Acad Sci U S A 2013; 110(51):20723-8; PMID:24297898.
28. Eser S, Schnieke A, Schneider G, Saur D. Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer 2014; 111, 817-822; PMID:24755884.
29. Armaghany T, Wilson JD, Chu Q, Mills G. Genetic alterations in colorectal cancer. Gastrointest Cancer Res 2012; 5(1):19-27. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24603996; PMID:22574233
30. Goodsell DS. The molecular perspective: the ras oncogene. Oncologist. 1999; 4(3):263-4; PMID:10394594
31. Alberts SR. K-ras inhibitors and pancreatic cancer. Pancreatic Cancer M. D. Anderson Solid Tumor Oncol Ser 2008; 601-7. http://link.springer.com/chapter/10.1007%2F978-0-387-69252-4-35
32. Wang J-Y, Wang Y-H, Jao S-W, Lu CY, Kuo CH, Hu HM, Hsieh JS, Chong IW, Cheng TL, Lin SR. Molecular mechanisms underlying the tumorigenesis of colorectal adenomas: correlation to activated K-ras oncogene. Oncol Rep 2006; 16:1245-52; PMID:17089045
33. Slebos RJC, Hoppin JA, Tolbert PE, et al. K-ras and p53 in pancreatic cancer: association with medical history, istopathology, and environmental exposures in a population-based study. 2000; 9(11) 1223-32; PMID:11097231
34. Claire Coeshott, Tom Holmes, Alicia Mattson, et al. Immune responses to mutated ras - development of a yeast based immunotherapeutic. In AACR-RAS Oncogene Conference 2014.
35. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57:1731-4; PMID:9135016
36. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002; 2(12):897-909.
37. Collins MA, Bednar F, Zhang Y, Brisset JC, Galbán S, Galbán CJ, Rakshit S, Flannagan KS, Adsay NV, Pasca di Magliano M. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. 2012; 122(2):639-53; PMID:22232209.
38. Di Magliano MP, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology 2013; 144(6):1220-9; PMID:23622131
39. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, et al. Oncogenic kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012; 149(3):656-70; PMID:22541435.
40. Berndt N, Hamilton AD, Sebti SM. Targeting protein prenylation for cancer therapy. Nat Rev Cancer 2011; 11: 775-791; PMID: 22020205
41. Donald A. Richards PMTB-SLSWVVJRPJ, flynn WEFSHWCTTHCCAM, heinrich roder JRACTCR. a proteomic signature predicts response to a therapeutic vaccine in pancreas cancer; analysis from the GI-4000-02 trial. In: AACR Annual Meeting 2014; Abstract #5314.
42. Fruci D, Lo Monaco E, Cifaldi L, Locatelli F, Tremante E, Benevolo M, Giacomini P. T and NK cells: two sides of tumor immunoevasion. J Transl Med 2013; 11:30. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3621684&tool=pmcentrez&rendertype=abstract; PMID:23379575.
43. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144(5):646-74; PMID:21376230.
44. Yang L, Pang Y, Moses HL. TGF-Beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010; 31(6):220-7; PMID:20538542.
45. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009; 182(8):4499-506; PMID:19342621.
46. Chatterjee B, Smed-Sörensen A, Cohn L, Chalouni C, Vandlen R, Lee BC, Widger J, Keler T, Delamarre L, Mellman I. Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood 2012; 120(10):2011-20; PMID:22791285.
47. Heath WR, Carbone FR. Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat Immunol 2009; 10(12):1237-44. Available at: http://www.nature.com.proxy.library.georgetown.edu/ni/journal/v10/n12/full/ni.1822.html.Accessed-May-2,2014; PMID:19915624; http://dx.doi.org/10.1038/ni.1822
48. Fehres CM, Unger WWJ, Garcia-Vallejo JJ, van Kooyk Y. Understanding the biology of antigen cross-presentation for the design of vaccines against cancer. Front Immunol 2014; 5:149. Available at: http://www.frontiersin.org/Journal/10.3389/fimmu.2014.00149/abstract. Accessed May 1, 2014.
49. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007; 67(19):9518-27; PMID:17909062.
50. Collins MA, Pasca di Magliano M. Kras as a key oncogene and therapeutic target in pancreatic cancer. Front Physiol 2013; 4:407; PMID:24478710.
51. Vonderheide RH, Bayne LJ. Inflammatory networks and immune surveillance of pancreatic carcinoma. Curr Opin Immunol 2013; 25(2):200-5; PMID:23422836.
52. Steele CW, Jamieson NB, Evans TRJ, McKay CJ, Sansom OJ, Morton JP, Carter CR. Exploiting inflammation for therapeutic gain in pancreatic cancer. Br J Cancer 2013; 108(5):997-1003; PMID:23385734.
53. Soares KC, Zheng L, Edil B, Jaffee EM. Vaccines for pancreatic cancer. Cancer J 2012; 18(6):642-52. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3539747&tool=pmcentrez&rendertype=abstract; PMID:23187853.
54. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53(4):549-54; PMID:2453289.
55. Smit VT, Boot AJ, Smits AAM, Fleuren GJ, Cornelisse CJ, Bos JL. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res. 1988 Aug 25;16(16):7773-82; PMID:3047672.
56. Niccolai E, Prisco D, D'Elios MM, Amedei A. What is recent in pancreatic cancer immunotherapy? Biomed Res Int 2013; 2013: 492372 PMID:23509731.
57. Koido S, Homma S, Takahara A, Namiki Y, Tsukinaga S, Mitobe J, Odahara S, Yukawa T, Matsudaira H, Nagatsuma K, et al. Current immunotherapeutic approaches in pancreatic cancer. Clin Dev Immunol 2011; 2011:267539; PMID:21922022.
58. Shahda S, O'Neil B. GI-4000 in KRAS mutant cancers. Expert Opin Investig Drugs 2014; 23(2):273-8. Available at: http://informahealthcare.com/doi/abs/10.1517/13543784.2014.876408. Accessed May 5, 2014; PMID:24372276; http://dx.doi.org/10.1517/13543784.2014.876408
59. Sam H, Whiting Peter, Muscarella E, Rosenmurgy William E, Fisher Donald A, Richards Frank Harrell Jr., John Ferraro, Sue Speyer, Allen Cohn. A randomized, placebo-controlled, multicenter phase II adjuvant trial of the efficacy, immunogenicity, and safety of GI-4000 plus gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer with activating ras mutations. J Clin Oncol 28:15s, 2010 (suppl; abstr TPS226). Available at: http://meetinglibrary.asco.org/content/42584-74 (accompanying poster).
60. GloboImmune. GlobeImmune powerpoint presentation: recombinant DNA advisory committee - GI-6301. Available at: http://osp.od.nih.gov/sites/default/files/1-1107-1119-Gulley.pdf
61. Cohn A, Morse MA, O'Neil B, et al. Treatment of ras mutation-bearing solid tumors using whole recombinant S. cerevisiae yeast expressing mutated ras: preliminary safety and immunogenicity results from a phase 1 trial. J Clin Oncol 2005; 23(16s):2571
62. Chaft JE, Litvak A, Arcila ME, Patel P, D'Angelo SP, Krug LM, Rusch V, Mattson A, Coeshott C, Park B, et al. Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation. Clin Lung Cancer. 2014 Nov;15(6):405-10. PMID:25044103.
63. GlobeImmune, Inc. GlobeImmune Announces Presentation of GI-4000 Phase 2 Data at IASLC World Conference on Lung Cancer, GlobeNewswire Europe, October 27, 2013; 4:02 PM (Sydney, Australia, October 28, 2013).